MURA Stock Overview
A clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Mural Oncology plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.93 |
| 52 Week High | US$6.25 |
| 52 Week Low | US$2.88 |
| Beta | 0 |
| 11 Month Change | 11.97% |
| 3 Month Change | 24.76% |
| 1 Year Change | -2.96% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 3.42% |
Recent News & Updates
Recent updates
Here's Why We're Watching Mural Oncology's (NASDAQ:MURA) Cash Burn Situation
Nov 26
Here's Why We're A Bit Worried About Mural Oncology's (NASDAQ:MURA) Cash Burn Situation
Jul 17We're Keeping An Eye On Mural Oncology's (NASDAQ:MURA) Cash Burn Rate
Mar 28Recent Spin Mural Oncology At An Attractive Discount To Cash And Portfolio Value
Mar 04Shareholder Returns
| MURA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 16.6% | 4.0% | 2.0% |
| 1Y | -3.0% | 18.0% | 32.4% |
Return vs Industry: MURA underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: MURA underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| MURA volatility | |
|---|---|
| MURA Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MURA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MURA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 109 | Caroline Loew | www.muraloncology.com |
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors.
Mural Oncology plc Fundamentals Summary
| MURA fundamental statistics | |
|---|---|
| Market cap | US$66.10m |
| Earnings (TTM) | -US$153.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs MURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MURA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$153.78m |
| Earnings | -US$153.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MURA perform over the long term?
See historical performance and comparison